Streetbeat News

Price Targets

MKC

B of A Securities analyst Peter Galbo maintains a Buy rating on McCormick & Co (NYSE:MKC) but lowers the price target from $100 to $86.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 10:45 am

LTH

Wells Fargo analyst Daniel Politzer has upgraded Life Time Group Holdings (LTH) from Underweight to Equal-Weight and set a price target of $17.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 10:42 am

OLPX

Barclays analyst Lauren Lieberman has upgraded Olaplex Hldgs (NASDAQ:OLPX) from Underweight to Equal-Weight and set a price target of $2.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 10:40 am

ODD

B of A Securities analyst Lorraine Hutchinson has upgraded ODDITY Tech (NASDAQ:ODD) from Neutral to Buy, but lowered the price target from $60 to $37.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 10:32 am

OCUL

HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on Ocular Therapeutix (NASDAQ:OCUL) and maintained a $12 price target.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 10:28 am

ACRS

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Aclaris Therapeutics (NASDAQ:ACRS) and maintained a $43 price target.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 10:22 am

GM

CFRA analyst Garrett Nelson has upgraded General Motors (NYSE:GM) from Strong Sell to Sell, while maintaining a $28 price target.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 10:22 am

RMTI

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Rockwell Medical (NASDAQ:RMTI) and maintained a price target of $11.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 10:20 am

COCP

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Cocrystal Pharma (NASDAQ:COCP) and maintained a $12 price target.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 10:18 am

URGN

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on UroGen Pharma (NASDAQ:URGN) and maintained a price target of $54.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 10:16 am